Prevent Fraud in Healthcare

Scott led the Medicare and Medicaid Fraud Prevention Act, which requires state Medicaid programs to check providers against the Social Security Death Master File at enrollment and at least quarterly after that. Congress enacted the bill as part of the 2025 reconciliation law.

Awareness for Tardive Dyskinesia

For the past four years, Scott has led a bill to recognize Tardive Dyskinesia Awareness Week. Tardive dyskinesia is a persistent and potentially disabling involuntary movement disorder that is associated with taking certain medications prescribed to treat mental illness. TD affects approximately 600,000 people in the United States, and approximately 60 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms.

Ensure Medicaid Coverage for Genomic Sequencing in Children

Scott led the Genomic Answers for Children’s Health Act, a bill to clarify that children enrolled in Medicaid who have a suspected rare disease or genetic disorder can access genomic sequencing, a diagnostic tool that has quickly become the standard of care, to help get answers more quickly.

Improve Discount Drug Pricing Program 

Scott has been one of the more persistent voices in Congress pushing to reform the 340B drug discount program. Scott led the SECURE 340B Act which expands oversight, transparency, and patient protections in the 340B drug pricing program. This the first-ever comprehensive bipartisan proposal to modernize the 340B Drug Pricing Program since its creation in 1992.

Improve Drug Price Negotiation Program

Scott co-led the ORPHAN Cures Act which fixes the Inflation Reduction Act’s orphan drug exclusion, so it no longer penalizes treatments for more than one rare disease. Congress enacted the bill as part of the 2025 reconciliation law and since then, more than 27 orphan drugs have received follow-on orphan drug designations to help patients who previously had no treatment options. 

Medical Device Safety

Scott co-led the Clarifying Remanufacturing to Protect Patient Safety Act, which specifies that entities that remanufacture medical devices in a manner that could change the performance or safety specifications or the intended use of the device must register with the Food and Drug Administration as producers of medical devices and comply with related requirements.

Lower Prescription Drug Costs 

Scott co-led the Reduced Costs and Continued Cures Act, lowering patients' prescription drug costs and protect our nation's ability to find cures. The plan is the first ever to cap out-of-pocket costs for seniors, addresses loopholes in the health care system and provides the most generous benefits to the most disadvantaged Americans.

Modernize Public Health Data Systems

Scott co-led the Health STATISTICS Act, helping to achieve better patient outcomes and will save more lives by providing researchers with greater access to higher quality data. It will modernize the nation's data infrastructure so that public health infrastructure can meet immediate surveillance, reporting, and other outbreak management needs.

Youth Suicide Prevention

Scott led the STANDUP Act of 2021 to encourage schools to adopt evidence‑based suicide prevention training for students in grades 6–12. The bipartisan measure requires states, schools, and Tribes to implement threat‑identification and prevention training to qualify for Project AWARE grants, which support youth mental health awareness in schools and communities.

Cannabis Research

Scott co-led to Cannabis Research Act providing legal certainty to researchers studying state-legal cannabis products. A comprehensive agenda for federal cannabis research will help empower America’s best and brightest researchers to work together to solve unanswered scientific questions about cannabis use. He also co-led the Developing and Nationalizing Key Cannabis Research Act to try to close the knowledge gap by setting a national research agenda for studying marijuana.

Expand Access to Nuclear Diagnostics

Scott co-led the Facilitating Innovative Nuclear Diagnostics (FIND) Act expanding access to highly targeted, precision radiopharmaceutical diagnostics so patients can receive the right treatment for diseases, such as Alzheimer's and Parkinson's, faster. Radiopharmaceuticals are small amounts of radioactive material used to capture molecular-level images of what is happening in a patient's body. Using radiopharmaceuticals during the diagnostic process can result in more accurate diagnoses, quicker treatment, higher quality care, and lower costs for patients and taxpayers.